|Bid||14.20 x 1400|
|Ask||0.00 x 1200|
|Day's range||34.88 - 37.50|
|52-week range||33.33 - 89.75|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||112.25|
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
LASR, TWLO, SWTX, FSLY, and UUUU have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2021